| Identification | Back Directory | [Name]
epiyangambin | [CAS]
24192-64-1 | [Synonyms]
epiyangambin
O,O-Dimethyllirioresinol A
Lirioresinol A dimethyl ether
(+)-Epipinoresinol dimethyl ether
3,6-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan
(1S,3aβ,6aβ)-1β,4α-Bis(3,4-dimethoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan
(1S,3aβ,6aβ)-Tetrahydro-1β,4α-bis(3,4-dimethoxyphenyl)-1H,3H-furo[3,4-c]furan
(1S)-1β,4α-Bis(3,4-dimethoxyphenyl)-3aβ,4,6,6aβ-tetrahydro-1H,3H-furo[3,4-c]furan
[1S,(+)]-1β,4α-Bis(3,4-dimethoxyphenyl)-3aβ,4,6,6aβ-tetrahydro-1H,3H-furo[3,4-c]furan
1H,3H-Furo[3,4-c]furan, tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-, (1R,3aR,4S,6aR)- | [Molecular Formula]
C24H30O8 | [MOL File]
24192-64-1.mol | [Molecular Weight]
446.49 |
| Hazard Information | Back Directory | [Uses]
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells)[1][2]. | [in vivo]
Epiyangambin (20 mg/kg) significantly inhibits PAF (platelet activating factor)-induced thrombocytopenia in rats[2]. | [References]
[1] Hausott B, et al. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol. 2003 Oct;129(10):569-76. DOI:10.1007/s00432-003-0461-7
[2] Castro-Faria-Neto HC, et al. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity. J Lipid Mediat. 1993 May;7(1):1-9. PMID:8358020 |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|